Clinical Trial to Evaluate ANT-1401 in Crow's Feet

Clinical Trial to Evaluate ANT-1401 in Subjects With Lateral Canthal Lines

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01809964

Enrollment

109

Registered

2013-03-13

Start date

2013-03-31

Completion date

2013-10-31

Last updated

2014-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crows Feet, Lateral Canthal Lines

Brief summary

The purpose of this study is to confirm the effect of ANT-1401 in the treatment of Lateral Canthal Lines.

Interventions

BIOLOGICALANT-1401

BIOLOGICALVehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* 30 - 60 years of age * mild to moderate Crow's Feet wrinkles (IGA 1-2) at rest * moderate to severe Crow's Feet (IGA 2-3) on contraction * moderate to severe Crow's Feet (SSA 2-3) on contraction * Have adequate vision to assess facial wrinkles in a mirror

Exclusion criteria

* botulinum toxin treatment in the prior 6 months * history of periocular surgery, brow lift or related procedures * soft tissue augmentation in the lateral canthal region in the prior 12 months * dermabrasion or laser treatment in the periocular region in the last 6 months * topical prescription-strength retinoids in the prior 3 months * present or history of neuromuscular disease * present or history of dry eye * systemic aminoglycoside use in the week prior to treatment application

Design outcomes

Primary

Measure	Time frame
Investigator's Global Assessment Scale	Week 4

Secondary

Measure	Time frame
Subject Self-Assessment	Week 4

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026